Developmental patterns in human blood–brain barrier and blood–cerebrospinal fluid barrier ABC drug transporter expression by Verscheijden, L.F.M. (L. F.M.) et al.
Vol.:(0123456789) 
Histochemistry and Cell Biology 
https://doi.org/10.1007/s00418-020-01884-8
ORIGINAL PAPER
Developmental patterns in human blood–brain barrier 
and blood–cerebrospinal fluid barrier ABC drug transporter 
expression
L. F. M. Verscheijden1  · A. C. van Hattem1 · J. C. L. M. Pertijs1 · C. A. de Jongh1 · R. M. Verdijk2  · B. Smeets3  · 
J. B. Koenderink1  · F. G. M. Russel1  · S. N. de Wildt1,4 
Accepted: 8 May 2020 
© The Author(s) 2020
Abstract
When drugs exert their effects in the brain, linear extrapolation of doses from adults could be harmful for children as the 
blood–brain barrier (BBB) and blood–CSF barrier (BCSFB) function is still immature. More specifically, age-related vari-
ation in membrane transporters may impact brain disposition. As human data on brain transporter expression is scarce, age 
dependent [gestational age (GA), postnatal age (PNA), and postmenstrual age (PMA)] variation in immunohistochemical 
localization and staining intensity of the ABC transporters P-glycoprotein (Pgp), breast cancer resistance protein (BCRP), 
and multidrug resistance-associated proteins 1, 2, 4, and 5 (MRP1/2/4/5) was investigated. Post mortem brain cortical and 
ventricular tissue was derived from 23 fetuses (GA range 12.9–39 weeks), 17 neonates (GA range 24.6–41.3 weeks, PNA 
range 0.004–3.5 weeks), 8 children (PNA range 0.1–3 years), and 4 adults who died from a wide variety of underlying 
conditions. In brain cortical BBB, immunostaining increased with age for Pgp and BCRP, while in contrast, MRP1 and 
MRP2 staining intensity appeared higher in fetuses, neonates, and children, as compared to adults. BCSFB was positively 
stained for Pgp, MRP1, and MRP2 and appeared stable across age, while BCRP was not detected. MRP4 and MRP5 were 
not detected in BBB or BCSFB. In conclusion, human BBB and BCSFB ABC membrane transporters show brain location 
and transporter-specific maturation.
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Introduction
ATP-binding cassette (ABC) drug transporters form a vital 
part of the blood–brain barrier (BBB) and blood–cerebrospi-
nal fluid barrier (BCSFB), where they mediate the efflux of 
a wide variety of chemical structures from endothelial and 
ependymal cells. Their specific localization and expression 
at the apical or basolateral plasma membrane impacts drug 
exposure in brain extracellular fluid (ECF) or cerebrospinal 
fluid (CSF) (Loscher and Potschka 2005; Morris et al. 2017).
ABC transporter localization has previously been estab-
lished in adult human brain. P-glycoprotein (Pgp), breast 
cancer resistance protein (BCRP), and multidrug resistance-
associated proteins (MRPs) 1, -2, -4, and -5 are expressed 
at the adult BBB (Morris et al. 2017; Nies et al. 2004). In 
addition, Pgp, MRP1 and MRP4 are present at the BCSFB, 
while this is debated for BCRP (Daood et al. 2008; Mor-
ris et al. 2017; Strazielle and Ghersi-Egea 2015). Together 
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with multiple influx transporters, ABC transporters mediate 
brain disposition of various drugs and both influx and efflux 
have been described to affect brain ECF concentrations of 
transporter substrates (Morris et al. 2017; Strazielle and 
Ghersi-Egea 2015). The importance of ABC transporters at 
the BBB and BCSFB is supported by mouse knock-out mod-
els resulting in increased brain ECF exposure of morphine 
(Pgp knockout model), topotecan (BCRP and Pgp knockout 
model), and methotrexate (MRP4 knockout model) (Kan-
amitsu et al. 2017; Shen et al. 2009; Xie et al. 1999). Human 
BBB drug–drug interaction studies showed increased brain 
exposure of vinblastine after inhibition of Pgp by tariquidar 
(Bauer et al. 2015). Hence, it is likely that inter-individual 
variation in brain transporters expression or activity will 
result in altered brain drug exposure and resultant clinical 
effects (Billington et al. 2019).
In fetuses, neonates and children, BBB and BCSFB 
transporter expression levels are expected to be different as 
compared to adults, as this has previously been described 
for liver, kidney, and intestine (Cheung et al. 2019; Mooij 
et al. 2014; Prasad et al. 2016; van Groen et al. 2018). The 
limited fetal and neonatal studies available suggest low BBB 
Pgp expression in fetuses, which increases after birth, sta-
ble BCRP expression, and the absence of MRP1 expres-
sion (Daood et al. 2008; Lam et al. 2015). BCSFB stain-
ing was positive in children for Pgp and MRP1, but not for 
BCRP (Daood et al. 2008). As the existing data are mainly 
restricted to (young) fetuses, we now aim to study the devel-
opmental patterns for the ABC transporters Pgp, BCRP, and 
MRP 1, -2, -4, and -5 in a unique cohort ranging from fetus 
to infancy when compared to adults.
Materials and methods
Brain samples
The Erasmus MC Research Ethics Board waived the need 
for formal ethics approval according to the Dutch Law on 
Medical Research in Humans. Brain cortex and brain ven-
tricle/choroid plexus tissue was collected when parental 
written informed consent for both autopsy and the explicit 
use of the tissue for research was present. The samples 
were selected when the tissue was morphologically nor-
mal. Tissues were derived from stillbirths or patients who 
passed away postnatally due to a wide variety of underly-
ing conditions, which may have influenced brain function 
and possibly also BBB and/or BCSFB transporter protein 
expression. Examples of these conditions include, intrau-
terine infections, congenital anomalies and intrauterine 
growth retention, necrotizing enterocolitis, and heart dis-
ease. Human adult kidney tissue samples were a gift from 
Bart Smeets, PhD (Radboud University Medical Center, 
Nijmegen, The Netherlands) and human placental tissue 
samples from Rick Greupink, PhD (Radboud University 
Medical Center, Nijmegen, the Netherlands). These had 
been collected anonymously as (surgical) waste material. 
For these samples, a no-objection clause permitted use 
for research purposes in line with the Dutch guidelines on 
secondary use of human tissue.
Immunohistochemistry
The formalin fixed, paraffin-embedded tissue blocks were 
cut in 4 μm slices and mounted on positively charged glass 
slides. The slides of post mortem tissues were heated for 
25 min at 55 °C, deparaffinized and rehydrated in xylene 
and a series of ethanol. Depending on the transporter, 
antigen retrieval was performed with citrate buffer (pH6): 
Pgp, BCRP and MRP5 (“AMF”), or Tris–EDTA buffer 
(pH 9): MRP1, MRP2, MRP4, and MRP5 (“M5II-54”). 
Slides were incubated with a solution of 2% H2O2 (7047, 
Baker analyzed, Deventer, The Netherlands) in phosphate 
buffered saline (PBS)/Tween (0.1% Tween20 (T)) for 
half an hour, to quench endogenous peroxidase. Nonspe-
cific binding was blocked using a solution of 1% bovine 
serum albumin (BSA) in PBS/T for 1 h and slides were 
incubated with primary antibody (dilutions and manu-
facturers shown in Table 1) in PBS/T 1% BSA at 4 °C 
overnight in a humidified container. Negative controls 
were incubated with a solution of PBS/T 1% BSA without 
primary antibody. Secondary antibodies (Table 1) were 
diluted 500× in PBS and slides were incubated for 30 min. 
Avidin–biotin–HRP complex (ABC-kit, Vectastain elite 
PK-6100, Vector Laboratories, Burlingame, United States) 
incubation was performed for 30 min to amplify the stain-
ing intensity. A dilution of 3,3′-diaminobenzidine (DAB 
D4168, Sigma-Aldrich, Darmstadt, Germany) was applied 
to the tissue, rinsed with tap water, and counter stained 
with hematoxylin. After a new series of alcohol to dehy-
drate tissue, and immersion in xylene, slides were mounted 
with xylene-based mounting medium Mountex (41-4021-
00, MEDITE, Orlando, United States). IHC experiments 
were performed using a single batch of antibody and 
staining of all individual patient samples for a transporter 
protein of interest (e.g., Pgp) was performed in a single 
experiment in one run.
In case a transporter protein could not be detected in 
brain, kidney cortex (Pgp, BCRP, MRP1, -2, -4), and pla-
centa tissue (MRP5) were used as positive controls, because 
these tissues show expression for all transporters investi-
gated. The same procedure as described for brain samples 
was used, except that kidney material was blocked with an 
avidin and a biotin solution for 15 min, as kidney has high 
endogenous biotin expression.
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Microscopic imaging and quantification
Slides were scanned using the Slide Scanner Pannoramic 250 
(3D Histech, brightfield, 3CCD camera, 45× magnification) 
and visualized using Pannoramic viewer version 1.15.2. Stain-
ing intensity was assessed separately for brain microvessels 
in the cortex regions (BBB), choroid plexus, and ventricular 
ependyma (both BCSFB). Subsequently, slides were scored: 
negative (0), detectable (1), intermediate (2) or high (3) by two 
independent observers (LV, AH) as previously performed by 
Daood et al. (2008), and scores were averaged in case of a dis-
crepancy between scored values. Staining intensity scores were 
represented in scatterplots and a grouped analysis was done 
as performed by Cheung et al. using the age groups: preterm 
newborns (PNA 0–28 days; GA < 37 weeks), newborns (PNA 
0–28 days), infants (1–24 months), children (2–12 years), and 
adults (> 16 years) (Cheung et al. 2019). Owing to the low 
amount of samples, the age groups infants and children were 
combined.
Statistics
The data were described using standard statistics. To test for 
correlations between staining intensity score and postmen-
strual-, postnatal-, and gestational age (PMA, PNA, and GA), 
a Spearman’s rank correlation coefficient was calculated using 
Graphpad Prism version 5.03.
Results
Patient characteristics
Post mortem brain cortex tissue derived from 23 fetuses 
(1 first trimester, 10 second trimester, and 12 third trimes-
ter, GA range 12.9–39 weeks), 17 neonates (GA range 
24.6–41.3 weeks, PNA range 0.004–3.5 weeks), 8 children 
(PNA range 0.1–3 years), and 4 adults were obtained from 
the Erasmus MC Tissue Bank, Rotterdam. For 15 fetuses 
and children ventricle/choroid plexus tissue (BCSFB) was 
available.
Transporter localization and expression
P‑glycoprotein
BBB: An age dependent increase was observed for Pgp 
staining intensity score as a function of PMA, GA and PNA 
in cortex microvessels (Fig. 1; Table 2). Samples showing 
low or no staining were mainly from individuals with a PMA 
between 13 and 40 weeks.
BCSFB: Positive staining was observed for choroid plexus 
and ventricular ependymal cells as early as 12.9 weeks 
PMA. No age-related differences in staining intensity were 
observed (Fig. 2). Staining in ventricle ependymal cells was 
restricted to the apical membrane (Fig. 3).
Table 1  Antibodies used
Protein Primary antibody Antigen retrieval Dilution Supplier
Pgp HPA002199 (host: rabbit) Citrate buffer (pH 6) 1:200 Sigma-Aldrich
BCRP BXP-21 (host: mouse) Citrate buffer (pH 6) 1:250 Kamiya biomedical
MRP1 QCRL-1 (host: mouse) Tris–EDTA (pH 9) 1:66 Sigma-Aldrich
MRP2 M2 III-6 (host: mouse) Tris–EDTA (pH 9) 1:50 Millipore
MRP4 M4I-80 (host: rat) Tris–EDTA (pH 9) 1:20 Abcam
MRP4 M4I-10 (host: rat) Tris–EDTA (pH 9) 1:75 Santa Cruz
MRP5 M5II-54 (host: rat) Tris–EDTA (pH 9) 1:25 ThermoFisher
MRP5 AMF (host: rabbit) Citrate buffer (pH 6) 1:20 Jedlitschky et al. 
(2000), Nies et al. 
(2004)
Secondary antibody Dilution Supplier
Rabbit anti-mouse AS09 609 1:500 Agrisera
Swine anti-rabbit E 0431 1:500 DAKO
Rabbit anti-rat R1371B 1:500 Origen
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Breast cancer resistance protein
BBB: BCRP-staining intensity related to age as a function 
of PMA and GA (Fig. 2, Table 2). Staining variability was 
especially marked around 13–40 weeks PMA. In this age 
period, staining intensity was low in several samples, which 
was not seen in older children and adults.
BCSFB: No staining was detected in choroid plexus or 
ventricle ependymal cells (Fig. 3).
Multidrug resistance‑associated protein 1
BBB: MRP1 staining was weakly positive in part of the 
brain cortical vessels in fetal and pediatric samples (between 
13 and 40 weeks PMA), but not in adults. For a few samples, 
clear staining of vessels could be seen at a PMA between 30 
and 40 weeks (Figs. 2, 3).
BCSFB: Staining was pronounced in choroid plexus and 
ventricular epithelium, but no age-related effects could be 
observed at this barrier. In ventricular epithelium, staining 
could be observed only at the apical membrane (Figs. 2, 3).
Multidrug resistance‑associated protein 2
BBB: For most samples, staining intensity of MRP2 
appeared higher until 100 weeks PMA, as compared to adult 
material by visual inspection (Fig. 2). No significant correla-
tion was observed between MRP2 and age (Table 2).
BCSFB: MRP2 staining was positive in choroid plexus 
and ventricle wall ependymal cells, but no developmental 
pattern could be seen. The expression in ventricle epithe-
lium was detected at the apical side of the ependymal cells 
(Figs. 2, 3).
Multidrug resistance‑associated protein 4
MRP4 could not be detected in brain cortex microvessels, 
choroid plexus, or ventricular ependymal cells (data not 
shown). MRP4 was detected in positive control kidney cor-
tex material using two different antibodies (Online Resource 
1).
Multidrug resistance‑associated protein 5
Staining in brain cortex microvessels was only positive 
in erythrocytes in these vessels. Staining in microvessel 
PMA(wks)
BBB Pgp intensity score
a
b
c
GA(wks)
PNA(wks)
Fig. 1  Pgp staining intensity scores in BBB against a postmenstrual 
age, b gestational age, and c postnatal age. wks indicates age in weeks
Table 2  Correlation of BBB 
staining intensity score with age
PMA postmenstrual age, GA gestational age, PNA postnatal age
ρ = Spearman’s correlation coefficient. Bold = statistically significant (p < 0.05)
Transporter 
protein
PMA GA PNA
Pgp ρ = 0.5351, p = < 0.0001 ρ = 0.4423, p = 0.0009 ρ = 0.2854, p = 0.0383
BCRP ρ = 0.4303, p = 0.0013 ρ = 0.4350, p = 0.0011 ρ = 0.2604, p = 0.0597
MRP1 ρ = − 0.1164, p = 0.4209 ρ = − 0.1052, p = 0.4670 ρ = − 0.1988, p = 0.1663
MRP2 ρ = − 0.1556, p = 0.2708 ρ = − 0.06476, p = 0.6450 ρ = − 0.2340, p = 0.0917
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endothelial cells, choroid plexus, or ventricle was not 
detected (data not shown). MRP5 was stained in placental 
tissue used as positive control with two different antibodies 
(Online Resource 1).
Gestational and postnatal age versus transporter 
expression
Online Resources 2 and 3 present the staining intensity 
of the brain cortex BBB transporters BCRP, MRP1 and 
MRP2 and BCSFB transporters Pgp, MRP1, and MRP2 
in relation to postnatal and gestational age.
Grouped analysis of brain cortex BBB transporter 
expression
Online Resource 4 presents the staining intensity of the 
brain cortex BBB transporters Pgp, BCRP, MRP1, and 
MRP2 in the age groups defined previously.
BBB MRP2 intensity score
10 100
0
1
2
3
1000 10000
sc
or
e
BBB MRP1 intensity score
10 100
0
1
2
3
1000 10000
sc
or
e
BBB BCRP intensity score
10 100
0
1
2
3
1000 10000
sc
or
e
BCSFB MRP2 intensity score
0 10 20 30 40 50
0
1
2
3
sc
or
e
a
b
c
BCSFB Pgp intensity score
0 10 20 30 40 50
0
1
2
3
sc
or
e
BCSFB MRP1 intensity score
0 10 20 30 40 50
0
1
2
3
sc
or
e
PMA(wks)
PMA(wks)
PMA(wks) PMA(wks)
PMA(wks)
PMA(wks)
d
e
f
Fig. 2  Postmenstrual age (PMA) versus staining intensity score in 
BBB for a BCRP, b MRP1, c MRP2 and postmenstrual age versus 
staining intensity score in BCSFB for d Pgp, e MRP1, f MRP2. In 
panel d black dots indicate scoring of ventricle ependymal cells and 
gray dots scoring of choroid plexus. wks indicates age in weeks
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Fig. 3  Representative images from fetal and neonatal brain samples 
for Pgp, BCRP, MRP1, and MRP2 in microvessels (a, d, g, and j), 
choroid plexus (b, e, h, and k), and ventricle (c, f, i, and l). All tissues 
were from children < 45 weeks PMA. Arrows highlight locations of 
interest. Scale bar 50 μm
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Discussion
Our results show both location as well as transporter-specific 
variation in ABC transporter expression in young children 
as compared to adults. Pgp, BCRP, MRP1, and MRP2 were 
detected in the cortical BBB, although not across the complete 
age range. Staining intensity was lower for Pgp and BCRP 
in brain cortex microvessels from fetuses and neonates, as 
compared to adults. In contrast, MRP1 and MRP2 staining 
intensity appeared higher in fetuses, neonates and children, 
but a correlation with age was not statistically significant. Cho-
roid plexus and ventricle wall ependymal cells were positively 
stained for Pgp, MRP1, and MRP2 and intensity appeared sta-
ble. Transporter expression detected in ventricle was present at 
the apical side of ependymal cells for Pgp, MRP1 and MRP2, 
whereas plasma membrane localization could not be specified 
in microvessels and choroid plexus. MRP4 and MRP5 could 
not be detected in brain cortex microvessels, ventricular epi-
thelium, and choroid plexus.
P‑glycoprotein
Pgp expression has previously been described in brain cortex 
microvessels forming the BBB in fetal, pediatric, and adult 
animals and humans (Daood et al. 2008; Lam et al. 2015; Tsai 
et al. 2002; Uchida et al. 2011). In addition, weak Pgp staining 
of pericytes and astrocytes has been described in some studies, 
but this was not observed in our samples possibly due to the 
relatively high dilution of primary antibody (Virgintino et al. 
2002). Our observed increase in the expression with increas-
ing age is consistent with the literature and appeared mature at 
40 weeks postmenstrual age and less than 7 days PNA. In con-
trast, Lam et al. suggested full maturation around 3–6 months 
PNA (Lam et al. 2015). Our study is consistent with the results 
of Daood et al. where Pgp expression increased between 22 
and 42 weeks gestational age. Lower Pgp BBB expression in 
fetuses and neonates might result in an increase in brain ECF 
concentrations of Pgp substrates. For example, this mechanism 
could explain the increased risk of respiratory depression with 
morphine in neonates (Taddio et al. 2009). BCSFB expression 
of Pgp is present at the apical cell membrane in adults (Morris 
et al. 2017). This was also observed in our study for cells in 
the ventricle ependyma, which belong to the BCSFB. Reduced 
apical Pgp activity will result in a reduced efflux of substrates 
into the CSF. This is supported by decreased CSF concentra-
tions in a mouse Pgp knockout model with topotecan as Pgp 
(and BCRP) substrate (Shen et al. 2009).
Breast cancer resistance protein
BCRP cortical BBB staining intensity was variable, rang-
ing from low to adult levels in children between 13 weeks 
and 40 weeks PMA, after which expression became more 
consistently intense. This is in contrast with a previous study 
in which fetal and adult staining was similar (Daood et al. 
2008). Our study provides the first indication that dosing of 
BCRP substrates might result in higher brain ECF exposures 
due to lower BCRP expression in the fetal and neonatal age 
range. The lack of BCRP staining in choroid plexus and 
ventricle wall ependymal cells was similar across the com-
plete age range and consistent with low or no expression in 
human and animal studies (Daood et al. 2008; Eisenblatter 
et al. 2003; Reichel et al. 2011).
Multidrug resistance‑associated protein 1
In our study, pediatric MRP1 expression was detected in 
brain cortex BBB of some fetuses and children, in contrast 
to the study by Daood et al. (2008). Interestingly, others also 
found low or no MRP1 expression levels in adults using 
immunohistochemistry or western blotting (Aronica et al. 
2004; Nies et al. 2004; Regina et al. 1998). Consistent with 
the previous findings was the intense staining of MRP1 
in the choroid plexus and ventricle wall ependymal cells 
(Daood et al. 2008).
Multidrug resistance‑associated protein 2
MRP2 cortical BBB expression had an inverse pattern as 
compared to the developmental pattern seen for Pgp. This is 
consistent with studies in adult brain tissue, where generally 
no expression was seen and only in case of epilepsy or asso-
ciated co-medication MRP2 becomes upregulated (Aronica 
et al. 2004; Dombrowski et al. 2001; Luna-Munguia et al. 
2015). This is the first time that BBB expression has been 
evaluated in a pediatric population and that intense staining 
intensity was observed for pediatric samples. MRP2 was 
also detected in choroid plexus ependymal cells and ventri-
cle ependymal cells.
Multidrug resistance‑associated protein 4 and 5
MRP4 and MRP5 were not detected in cortical BBB epi-
thelial cells or BCSFB ependymal cells. MRP5 was stained 
in erythrocytes retained in the microvessels, which con-
firms earlier reports of MRP5 expression in red blood cells 
(Jedlitschky et al. 2000). This is in contradiction to find-
ings by Nies et al. who described MRP4 and MRP5 staining 
in microvessels, and also with proteomic analysis of brain 
microvessels and the brain endothelial hCMEC/D3 cell line, 
in which MRP4 was detected (Nies et al. 2004; Ohtsuki et al. 
2013; Uchida et al. 2011). These differences can potentially 
be explained by the disease state or previous drug treatment 
in the study by Nies et al., as this is known to influence 
transporter expression levels (Gu and Manautou 2010; Nies 
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et al. 2004). Also, cell culture conditions affect transporter 
expression levels. In our study, post mortem material was 
obtained from a heterogenous patient population.
If we compared BBB and BCSFB expression with trans-
porter expression in other organs, it becomes apparent that 
ontogeny is transporter and organ dependent. Pgp consist-
ently shows low to high expression while age increases 
in brain, kidney and liver, but remains stable in intestine 
(Cheung et al. 2019; Daood et al. 2008; Konieczna et al. 
2011; Prasad et al. 2016; van Groen et al. 2018). For MRP1 
and MRP2 a trend towards a high to low expression profile 
as a function of PMA was observed in this study, whereas 
an age-related increase in liver expression is described (van 
Groen et al. 2018). Ontogeny in MRP2 kidney expression 
appears stable, while MRP1 remained undetected (Cheung 
et al. 2019). In addition, BCRP expression was relatively sta-
ble in kidney and liver (Cheung et al. 2019; van Groen et al. 
2018). An important aspect to consider is whether to cor-
relate transporter expression with postnatal age, gestational 
age or postmenstrual age. This will be dependent on factors 
driving expression, such as changes in transcription factors, 
epigenetics and hormones, and the moment they become 
important during development (e.g., as a consequence of 
birth). To date little is known about factors mediating trans-
porter expression differences (Cheung et al. 2019).
A limitation of our study is the use of immunohistochemi-
cal staining to assess an age-related variation in ABC efflux 
transporter expression. As this method only allows semi-
quantitative analysis, we were able to describe develop-
mental patterns, but not quantitative differences. Moreover, 
as discussed before, disease conditions, medication, delay 
between death and autopsy, and IHC methodology (e.g., 
methods of fixation) may have influenced the identified age-
related variation (Brouwer et al. 2015; Nicolas and de Lange 
2019). Reports have indicated that especially inflammation 
and ischemia influence transporter expression in transporter 
protein and organ dependent fashion (Evers et al. 2018). In 
addition, some drugs act intracellularly and therefore the 
plasma membrane barrier needs to be passed at which trans-
porters might influence their disposition (Bendayan et al. 
2006; Lee et al. 2001; Scism et al. 2000; Wang and Welty 
1996). The limitations in these human studies warrant care-
ful interpretation of the findings. To support our findings, 
the expression patterns for Pgp increased with age, consist-
ent with the previous literature. This suggests that despite 
its limitations, the material we studied appeared suitable to 
investigate age-dependent trends in the expression patterns 
of Pgp and likely other ABC transporter proteins.
In conclusion, this study indicates that Pgp and BCRP 
BBB expression is low and more variable around birth, 
potentially resulting in higher brain ECF concentrations of 
transporter substrates, whereas MRP1 and MRP2 expression 
appeared high around birth, decreasing towards adulthood.
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